Abstract
Objective: To investigate the pharmacokinetics and pharmacodynamics of inhaled GSK961081 and fluticasone propionate (FP) given alone, concurrently and as a combination blend formulation.Methods: The study was double‐blind, double‐dummy, four‐way crossover. Twenty‐four healthy volunteers took single doses of the following in randomized order: (1) GSK961081 800 µg; (2) FP 500 µg; (3) GSK961081 800 µg and FP 500 µg as a blend formulation; and (4) GSK961081 800 µg and FP 500 µg concurrently via separate inhalers. The eLung breathing simulator was also used for the in vitro characterization of the formulations.Results: There was no pharmacokinetic interaction when GSK961081 and FP were administered concurrently. Mean Cmax and AUC(0−t) of GSK961081 were lower (∼20%) and mean Cmax and AUC(0−t) of FP were higher (two fold) following GSK961081/FP blend formulation compared to concurrent or the individual components alone. There was an increase in the FP in vitro ex‐throat dose for the GSK961081/FP blend from the eLung breathing simulator. Serum cortisol suppression was greater with GSK961081/FP blend, with lower (∼10%) cortisol levels than after GSK961081 + FP concurrent or FP alone.Conclusion: GSK961081/FP blend formulation was associated with an increase in FP systemic exposure and greater serum cortisol suppression.
Funding Information
  • GlaxoSmithKline

This publication has 22 references indexed in Scilit: